Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors - Test2 - elhamkhani - TriplyDB

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

http://www.wikidata.org/entity/Q27663972

about

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma The role of the ALK receptor in cancer biology Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs ALK and ROS1 as a joint target for the treatment of lung cancer: a review Emerging importance of ALK in neuroblastoma The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib Development of novel ACK1/TNK2 inhibitors using a fragment-based approach ALK and NSCLC: Targeted therapy with ALK inhibitors Deciphering the structural basis of eukaryotic protein kinase regulation A spatial simulation approach to account for protein structure when identifying non-random somatic mutations TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding.The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.Pseudokinases from a structural perspective Characterization of TAE684 as a potent LRRK2 kinase inhibitor.Brain Penetrant LRRK2 Inhibitor.Targeting ALK in neuroblastoma--preclinical and clinical advancements.ALK: a tyrosine kinase target for cancer therapy.L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.Inhibitors of anaplastic lymphoma kinase: a patent review.Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.Anaplastic lymphoma kinase: Role in cancer and therapy perspective.NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

P2860

Q24310296-8A992F3F-A463-428C-9B64-BB38C743A313 Q26738384-DC60F41C-2DDE-4CE6-8D93-8CDC34E4A9CE Q26769659-872669A3-77F5-4CAD-BE2B-E5022B4764EA Q26851392-5232C453-97AD-4917-85E5-9E9DB0550355 Q26858819-D6F94671-E06A-4F0F-8C67-052F3FBAFDF7 Q27671787-E0CF333A-E09D-4F11-B45C-5CCB95DBF893 Q27673414-1326569C-DCF9-49D6-9DEB-71DDDC44812D Q27678635-F91E56C0-9172-491B-AF0B-EB813DAB8474 Q27851591-38A204F6-FACB-4E8C-908C-33AA7626D658 Q27851660-4690E8C7-250B-4A87-944D-3D493AF53D1C Q27851672-6B6C2E32-A497-4B01-B6BE-869FF1C44169 Q27851681-69D2A611-DA59-4202-888E-5C2ABA220540 Q27851684-33CFF077-064A-438E-B7E5-FBA2C76AFCB1 Q27851710-C664DC86-7BDA-44EF-9808-90266861BD68 Q27853072-5CA753BA-4A6E-442E-A35D-7F1943123880 Q28257452-B4934016-F686-4E7F-AE14-1017D41E0B0A Q28393324-120753E7-EB7D-4923-ACE3-E41231EC5FBC Q28534399-B5DB7DB9-5EB7-4BF6-A235-6886179DD673 Q30364303-FD53A86B-1D77-4248-99CF-E2BAA9A1EADF Q33911863-3C7C4E85-560A-4E67-96D1-29712DDF7A94 Q34164591-9B26A451-B289-4AE6-BFFF-F6BC6A68D440 Q34353920-3FC2C656-9615-4318-BD0B-477B0D3F60EC Q35011473-99ED69C7-C41D-4C02-8C1F-7614BBE71F08 Q35166315-484EFA4F-EBB8-4F5A-9936-7E9C6B7A6BFA Q35447884-FE5F40EC-D57E-4BAD-A3CE-40BC6E3B9851 Q36208468-94C6EE53-E0C3-44CA-937D-97765A69B2E0 Q36305876-816995BE-527F-4692-B066-6CFE939598B5 Q36933081-50AAF05F-0D2A-45BD-99CA-7183C7D2CE7D Q37518624-970683C2-4D54-4807-9235-D4D1A2B95C4B Q37728989-52053387-8EEB-4DB2-BDED-203D550C14FC Q37801664-919FB4F2-0959-4D7A-812E-2F4CF083F839 Q37956044-BB31EBF8-2055-4682-B6F4-C34AC5A89F99 Q38010052-C60D7D1A-C84D-4FCC-B4F5-C48050B04D1B Q38183162-732DA89E-5673-4CFB-8BB2-47FF9F4B35AC Q38540135-C29165E0-FDBC-4B93-8847-59E5E28407DD Q38623421-CED98D3F-EC53-4902-86DD-A3DDD8CFAB28 Q38902511-45E32C15-6836-48C4-82C2-CEFBD04A5DB7 Q39032553-6D8EDB48-49C2-412D-91F5-DB842E030996 Q39158036-9D2D798A-019C-4001-AAEA-F70A85CB1831 Q39252246-7B90E5E0-D1D1-4154-ADC7-D5AF2F986869

P2860

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

http://www.wikidata.org/entity/Q27663972

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@ast

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@en

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@nl

type

label

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@ast

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@en

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@nl

prefLabel

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@ast

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@en

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@nl

P1433

Q27663972-98C71AE0-92DB-45FF-8202-CD4605B7A45D

P1476

Q27663972-7D7FFBEB-1B50-4F33-8419-A9DF75C21D3E

P2093

Q27663972-0F58D7B3-92BF-4296-8C6B-891ABC3DA8B8

Q27663972-11E6718C-964E-4867-AA94-0FBED41A5479

Q27663972-21F2515E-B604-4D7B-8CAE-BC49FF4B667C

Q27663972-3CA2E7B6-DC97-4FCE-983D-7E68BB40068A

Q27663972-42C0C5BE-3C96-43F5-8687-554472AA06FC

Q27663972-59935CCA-D86E-406B-9186-22B6960C9587

Q27663972-7317B113-D03C-45A5-99E1-5F385DCA8FCB

Q27663972-82560260-1A10-44B4-8755-D71B259A7F15

Q27663972-86D38E09-E946-4816-97BA-AE088019C546

Q27663972-ABCAEEE0-F36B-4076-BB1F-054AFE7337F1

P304

Q27663972-F4AEAC3E-E470-4CB8-BD6B-E2E40995F5BD

P31

Q27663972-022047BA-0BB5-4F38-8925-2FB167E7A5FB

P356

Q27663972-C02BCC4E-44F1-4B73-9E41-02BDC965D8CA

P407

Q27663972-983A1507-2B06-46B6-AAFF-53388306EC7E

P433

Q27663972-7703C3AA-2EC5-405B-9443-5E8F121A1368

P478

Q27663972-C9C45115-0A05-4587-93C7-619B810AC96C

P577

Q27663972-3541C493-D10F-4CEC-8200-B187A164DCC7

P5875

Q27663972-BE102A40-7024-4F56-8D5F-7F8020AAFBEF

P698

Q27663972-C02C1111-A4D8-455C-BF25-EA211DFFC6EE

P921

Q27663972-0E0E326E-F92D-4C0F-8AF5-54E5273B5C48

P356

P1433

P1476

Crystal structures of anaplast ...... ith ATP competitive inhibitors

@en

P2093

Andrea Lombardi Borgia

http://www.w3.org/2001/XMLSchema#string

Elena Ardini

http://www.w3.org/2001/XMLSchema#string

Gianpaolo Fogliatto

http://www.w3.org/2001/XMLSchema#string

Jay A Bertrand

http://www.w3.org/2001/XMLSchema#string

Luisa Rusconi

http://www.w3.org/2001/XMLSchema#string

M Beatrice Saccardo

http://www.w3.org/2001/XMLSchema#string

Marcella Nesi

http://www.w3.org/2001/XMLSchema#string

Maria Menichincheri

http://www.w3.org/2001/XMLSchema#string

Nilla Avanzi

http://www.w3.org/2001/XMLSchema#string

Paola Magnaghi

http://www.w3.org/2001/XMLSchema#string

P304

6813-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BI1005514

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45581981

http://www.w3.org/2001/XMLSchema#string

P698

20695522

http://www.w3.org/2001/XMLSchema#string

P921

crystal structure